All lobbying filings

Avenue Solutions

Avenue Solutions filed a Q3 report for Takeda Pharmaceuticals America, Inc. on October 20, 2026, reporting $50,000 in lobbying income.

Lobbying for Takeda Pharmaceuticals America, Inc. · Pharmaceutical company

As filed: AVENUE SOLUTIONS for TAKEDA PHARMACEUTICALS AMERICA, INC.

All filings by Avenue Solutions · Everything Takeda Pharmaceuticals America, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act

Bills named in this filing 1

H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.